Interstitial lung disease (ILD) is a term that is used to describe a large group of lung conditions, most of which cause scarring (fibrosis) of lung tissue. This scarring makes the lungs stiff and harder for people to breathe.
to treat people with a chronic (long lasting) interstitial lung disease in which lung fibrosis continues to worsen (progress). or. to slow the rate of decline in lung function in people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) (also known as scleroderma-associated ILD).
The U.S. Food and Drug Administration today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive ...
Interstitial lung disease (ILD) encompasses over 200 conditions and involves scarring or inflammation in a space (or potential space) between alveoli and capillaries or blood vessels, a unique ...
Treatment for interstitial lung disease depends on the type and its underlying cause. Antibiotics: These medications can be given if interstitial pneumonia is caused by bacteria. Antifungal agents are given to treat pneumonia caused by fungus. Viral pneumonias don’t require any treatment.
Interstitial Lung Disease. Accessed 6/26/2020. American Lung Association. Interstitial Lung Disease (ILD). Accessed 5/7/2018. American Lung Association. Signs of Potential Problems in the Workplace. Accessed 5/7/2018.
Learn about the following ways the NHLBI continues to translate current research into improved health for people who have an interstitial lung disease. Research on this topic is part of the NHLBI’s broader commitment to advancing scientific discovery on lung diseases. The NHLBI Stimulates New Treatment Approaches for Lung Disease.
Interstitial lung disease is usually diagnosed by using a combination of blood tests, breathing tests, a chest X ray, a high resolution CT (HRTC) scan of your chest, and a stress test to determine the function of the lungs.In some cases a lung biopsy is also required when the ILD is confirmed by other tests.
The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease. A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment Scottsdale/Phoenix, AZ
Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32:296. Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.